Topical Finasteride: What It Is, and How It's Different From What We Sell

Topical finasteride is a prescription-only preparation of finasteride, the same drug sold as an oral tablet, made up as a scalp solution or spray, usually by a compounding pharmacy, rather than sold as a single standardised product. It works by blocking an enzyme called 5-alpha-reductase, which lowers how much dihydrotestosterone (DHT) reaches the scalp, and DHT is the hormone most closely linked to the follicle shrinkage seen in pattern hair loss. If you have seen it advertised alongside minoxidil and assumed the two belong to the same category, they do not: Quintéa's regrowth range is built entirely around topical minoxidil, and we do not sell finasteride in any form, topical or oral.

• Topical finasteride blocks the DHT pathway, while minoxidil works through a separate mechanism involving blood flow and the hair growth cycle, so neither is a stronger or weaker version of the other.
• It is not an FDA-approved product in its own right. When someone gets hold of it, it typically comes from a compounding pharmacy on prescription, which means the concentration and base can differ between pharmacies.
• The best available study is retrospective, has no placebo or comparison arm, and relies on self-reported adherence, so it shows change over time rather than proof that topical finasteride matches or beats an established option.
• Quintéa sells topical minoxidil, not finasteride in any form, and we will not advise on starting, stopping or dosing a prescription drug we do not sell.

What Topical Finasteride Actually Is

Finasteride is a 5-alpha-reductase inhibitor. That enzyme converts testosterone into DHT, and DHT is the hormone most strongly implicated in the follicle miniaturisation behind male pattern hair loss (source: American Hair Loss Association). Taken as an oral tablet, finasteride is an approved treatment for exactly that reason. Applied to the scalp as a solution or spray instead, it is aimed at the same pathway, but delivered locally rather than through the bloodstream.

The important distinction is regulatory rather than purely chemical. Only topical minoxidil and oral finasteride currently hold FDA approval for hair loss (source: literature review, PMC). Topical finasteride does not have that approval as a standalone product, so when someone obtains it, it is usually compounded to order by a pharmacy under a prescription rather than manufactured and tested as one fixed formula. Because compounding pharmacies can vary the concentration, base and preparation method, a bottle labelled "topical finasteride" from one pharmacy is not guaranteed to match another in strength or formulation.

How Topical Finasteride Differs From Minoxidil

Minoxidil does not touch the DHT pathway at all. It is understood to act as a potassium-channel opener that widens blood vessels in the scalp and is thought to push resting follicles into a new growth phase, a mechanism unrelated to reducing DHT (source: Minoxidil, Wikipedia). Topical minoxidil received FDA approval for male pattern hair loss in 1988, on the strength of that different mechanism.

Because the two drugs act on separate pathways, one is not simply a stronger or gentler version of the other, and neither one substitutes cleanly for the other's evidence base. Some people use a DHT-blocker and minoxidil together under medical supervision, but that is a prescriber's decision about combining two distinct mechanisms, not a case of picking the more advanced option. Quintéa's own range is built around topical minoxidil specifically: Minoxidil Topical Solution USP, 5% and its foam equivalent are the products in the regrowth range, and neither contains finasteride in any form. Anyone who wants the fuller picture of how those minoxidil formats compare can read the complete guide to minoxidil solution, foam and spray.

What the Evidence on Topical Finasteride Actually Shows

The most detailed data available comes from a retrospective 52-week study of a 0.25% topical finasteride spray in 123 patients, which found hair-density gains of roughly 29 hairs per square centimetre in the frontotemporal area and 22 hairs per square centimetre at the vertex, with no systemic sexual side effects reported over that period (source: Clinical and Experimental Dermatology). Local irritation occurred in about 7.3% of participants.

Read the design alongside the numbers before drawing a conclusion from them. The study had no placebo group and no active-comparator arm, and it relied on patients reporting their own adherence rather than any independent check. That combination means it shows a change over time in people who used the spray and stayed on it, not proof that topical finasteride performs as well as, or better than, an established treatment.

A broader review of the published literature describes the overall evidence as early: few randomised controlled trials exist, and there is no standard concentration, formulation or dosing frequency across the studies that do exist, which makes it hard to compare results between them directly (source: literature review, PMC). Readers who want the equivalent trial-by-trial breakdown for minoxidil itself, which has a much larger evidence base, can find it in what the minoxidil trials actually show.

Why Fewer Reported Sexual Side Effects Isn't the Same as Zero Risk

The absence of reported systemic sexual side effects in that 52-week study is often the headline point people take away from topical finasteride research, so it is worth reading carefully rather than as a guarantee. Absorption into the bloodstream from a topical application is generally lower than from a tablet, which is the reasoning behind expecting fewer systemic effects. But "not reported in this particular study" is a narrower claim than "does not happen": the study was small, uncontrolled and short relative to how long people typically stay on a hair-loss treatment. Long-term, controlled data that would let anyone put an actual number on the risk is not available yet.

Getting Topical Finasteride Legally, and Why We Don't Guide Dosing

Topical finasteride is obtained through a licensed prescriber or a compounding pharmacy working from that prescription, not picked up over the counter (source: American Hair Loss Association). That remains true even though it is not FDA-approved as a standalone product: a doctor can still prescribe it as a compounded preparation, using their own clinical judgement about the patient in front of them. Whether a prescription is required or how that process works varies by country, and readers based outside the US can see how that plays out for minoxidil specifically in how prescription requirements differ by country, which covers the same regulatory theme.

Some people look at oral finasteride's documented side effects, erectile dysfunction, decreased libido and ejaculation problems, along with a specific pregnancy-handling warning, since broken or crushed tablets can be harmful if handled by someone who is or may become pregnant, and go looking for a topical route hoping to avoid them (source: MedlinePlus Drug Information). That reasoning is understandable, but it does not make the topical version dose-free or risk-free, and deciding whether to try it is a call for a prescriber who can weigh the evidence against a specific patient's history. Quintéa sells hair-care and scalp products, not prescription medicines, and we will not advise on starting, stopping or adjusting a dose for a drug we do not sell. If you are weighing that decision, a dermatologist or GP is the person to ask, and a broader comparison of over-the-counter and prescription routes is available in OTC minoxidil versus prescription options.

What Quintéa Actually Sells, and Where It Fits

The product in Quintéa's regrowth range is the Minoxidil Topical Solution USP, 5%, the FDA-approved active applied twice daily according to the label. It works through the vascular and follicle-cycle mechanism described above, and it is approved specifically for regrowth at the vertex, the top of the scalp.

The solution's inactive ingredients include propylene glycol, which carries the minoxidil into the skin and is also the ingredient most often behind itching or a dry, tight scalp. For anyone who finds that irritating, the Minoxidil Topical Aerosol, 5% (Foam) uses the same active ingredient at the same strength and leaves propylene glycol out of the base, which is a formulation change rather than a different drug or mechanism.

Neither product contains finasteride, and choosing between them comes down to how your scalp tolerates the solution's ingredients rather than which one is "stronger". If topical finasteride is genuinely what you are researching, the honest next step is a conversation with a prescriber who can assess your history and, if appropriate, arrange it through a compounding pharmacy. What Quintéa can offer is the minoxidil side of the picture: an approved active with a well-documented mechanism and a much larger body of trial evidence behind it.